Skip to main content
OpenTrials
Completed

NCT Number: NCT00894439

Study Evaluating BLI-489 and Piperacillin in Healthy Subjects

The purpose of this study is to evaluate how BLI-489 and piperacillin interact when given together to healthy subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Philadelphia, Pennsylvania, 19148, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men or women of non-childbearing potential, aged 18 to 50 years of age inclusive at screening.
  • Body mass index (BMI) in the range of 18 to 32 kg/m2 and body weight greater than or equal to 50 kg.
  • Healthy as determined by the investigator on the basis of the screening evaluations.
  • Nonsmoker of smoker of fewer than 10 cigarettes per day as determined by history.

Exclusion criteria

  • Presence of history of any disorder that may prevent the successful completion of the study.
  • History of drug abuse within 1 year.

Treatment and study plan

BLI-489/Piperacillin

Drug

BLI-489

Drug

Piperacillin

Drug

Primary outcomes

  1. Pharmacokinetics as evaluated by drug concentrations in the blood and urine.

    Time frame: 10 days

Secondary outcomes

  1. Safety as measured by the number of adverse events and serious adverse events.

    Time frame: 10 weeks

Sponsors and collaborators

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Industry

Registry information

Official study title

A Randomized, Open-label, Single-dose, 3-period Crossover Study to Describe the Pharmacokinetic Parameters of BLI-489 and Piperacillin When Administered Simultaneously Compared to When Each is Administered Alone.

Important dates

Study start
2009
Primary completion
2009
Study completion
2009
First posted
May 7, 2009
Registry last updated
Jul 17, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.